Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
MetadataShow full item record
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Version of record
Small cell lung cancer
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Cell Transformation, Neoplastic
Drug Resistance, Neoplasm
Positron Emission Tomography Computed Tomography
Receptor, Epidermal Growth Factor
Small Cell Lung Carcinoma
License start date
Lung Cancer, 111 pp. 65 - 68
Showing items related by title, author, creator and subject.
P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) Chih-Hsin Yang, J; Ou, S-H; De Petris, L; Gadgeel, S; Gandhi, L; Kim, D-W; Barlesi, F; Govindan, R; Dingemans, A-M; Crinò, L; Léna, H; Popat, S; Ahn, JS; Dansin, E; Golding, S; Bordogna, W; Balas, B; Morcos, PN; Zeaiter, A; Shaw, A (2017-01)